hydroxychloroquine has been researched along with Diathesis in 8 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the susceptibility to coronavirus disease 2019 (COVID-19) in patients with autoimmune conditions treated with antimalarials in a population-based study." | 1.62 | Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy. ( Bajocchi, G; Boiardi, L; Carrozzi, G; Cassone, G; Costantini, M; Croci, S; Galli, E; Giorgi Rossi, P; Gradellini, F; Mancuso, P; Marata, AM; Muratore, F; Pandolfi, P; Pipitone, N; Reta, M; Salvarani, C; Sandri, G; Viani, N, 2021) |
| "Mucormycosis is an invasive fungal infection (IFI) due to several species of saprophytic fungi, occurring in patients with underlying co-morbidities (including organ transplantation)." | 1.62 | Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipient - Case report and review of literature. ( Berlinrut, I; Chang, KM; Khatri, A; Wallach, F, 2021) |
| "Hydroxychloroquine is an agent used as a treatment but also considered as a prophylaxis for SARS-CoV-2 infection." | 1.56 | [SARS-CoV-2 infection in a patient treated by hydroxychloroquine and anti TNF α for Inflammatory Rheumatic Disease]. ( Bouchti, IE; Malek, SA, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 7 (87.50) | 2.80 |
| Authors | Studies |
|---|---|
| Parisi, S | 1 |
| Ditto, MC | 1 |
| Finucci, A | 1 |
| Fusaro, E | 1 |
| Osama El-Gendy, A | 1 |
| Saeed, H | 1 |
| Ali, AMA | 1 |
| Zawbaa, HM | 1 |
| Gomaa, D | 1 |
| Harb, HS | 1 |
| Madney, YM | 1 |
| Osama, H | 1 |
| Abdelrahman, MA | 1 |
| Abdelrahim, MEA | 1 |
| Salvarani, C | 1 |
| Mancuso, P | 1 |
| Gradellini, F | 1 |
| Viani, N | 1 |
| Pandolfi, P | 1 |
| Reta, M | 1 |
| Carrozzi, G | 1 |
| Sandri, G | 1 |
| Bajocchi, G | 1 |
| Galli, E | 1 |
| Muratore, F | 1 |
| Boiardi, L | 1 |
| Pipitone, N | 1 |
| Cassone, G | 1 |
| Croci, S | 1 |
| Marata, AM | 1 |
| Costantini, M | 1 |
| Giorgi Rossi, P | 1 |
| Caron, P | 1 |
| Malek, SA | 1 |
| Bouchti, IE | 1 |
| Huh, K | 1 |
| Ji, W | 1 |
| Kang, M | 1 |
| Hong, J | 1 |
| Bae, GH | 1 |
| Lee, R | 1 |
| Na, Y | 1 |
| Jung, J | 1 |
| Khatri, A | 1 |
| Chang, KM | 1 |
| Berlinrut, I | 1 |
| Wallach, F | 1 |
| Lajoie, J | 1 |
| Mwangi, L | 1 |
| Fowke, KR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Thyroid Function Tests and the Status of Thyroid Autoantibodies in Hospitalized Covid-19 Patients and Their Relationship With White Blood Cells, Neutrophil / Lymphocyte Ratio, c Reactive Protein, Fibrinogen, Procalcitonin, Ferritin and D-dimer[NCT04659200] | 20 participants (Actual) | Observational | 2020-09-01 | Completed | |||
| Limiting HIV Target Cells by Inducing Immune Quiescence in the Female Genital Tract[NCT02079077] | 91 participants (Actual) | Interventional | 2014-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
We will measure changes in the number of CD4+T cells expressing CCR5 at the female genital tract before and at the end of the study. (NCT02079077)
Timeframe: baseline and 8 weeks
| Intervention | percentage of cells (Median) |
|---|---|
| Acetylsalicylic Acid (ASA) | 17.60 |
| Hydroxychloroquine (HCQ) | 22.10 |
We will analyse reduce of immune activation by measuring change in T cell activation (CD69) between baseline and every month during drug administration phase (8 weeks). (NCT02079077)
Timeframe: Baseline and 8 weeks
| Intervention | percentage of cells (Mean) | |
|---|---|---|
| Average of CD4+CD69+ at baseline | Average of CD4+CD69+ T cells cells after treatment | |
| Acetylsalicylic Acid (ASA) | 4.04 | 4.9 |
| Hydroxychloroquine (HCQ) | 5.55 | 4.99 |
2 reviews available for hydroxychloroquine and Diathesis
| Article | Year |
|---|---|
Thyroid disorders and SARS-CoV-2 infection: From pathophysiological mechanism to patient management.
Topics: Angiotensin-Converting Enzyme 2; Apoptosis; Betacoronavirus; Coronavirus Infections; COVID-19; COVID | 2020 |
Preventing HIV infection without targeting the virus: how reducing HIV target cells at the genital tract is a new approach to HIV prevention.
Topics: Aspirin; Disease Susceptibility; Female; Genitalia, Female; HIV Infections; HIV Seronegativity; HIV- | 2017 |
6 other studies available for hydroxychloroquine and Diathesis
| Article | Year |
|---|---|
How to manage rheumatic patients during the coronavirus pandemic.
Topics: Antirheumatic Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Di | 2020 |
Bacillus Calmette-Guérin vaccine, antimalarial, age and gender relation to COVID-19 spread and mortality.
Topics: Aging; Antiviral Agents; BCG Vaccine; Chemoprevention; Chloroquine; Coronavirus Infections; COVID-19 | 2020 |
Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy.
Topics: Adult; Aged; Aged, 80 and over; Antimalarials; Antirheumatic Agents; Arthritis, Juvenile; Arthritis, | 2021 |
[SARS-CoV-2 infection in a patient treated by hydroxychloroquine and anti TNF α for Inflammatory Rheumatic Disease].
Topics: Antirheumatic Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 | 2020 |
Association of prescribed medications with the risk of COVID-19 infection and severity among adults in South Korea.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; COVID-19; Disease Susceptibility; Female; Humans; Hyd | 2021 |
Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipient - Case report and review of literature.
Topics: Aged; Anti-Infective Agents; Bacteremia; Catheter-Related Infections; Coinfection; Combined Modality | 2021 |